SlideShare ist ein Scribd-Unternehmen logo
1 von 48
Downloaden Sie, um offline zu lesen
4/18/2010
1
SEDIAAN STERIL
Dr.Heni Rachmawati
SCHOOL OF PHARMACY - ITB
PENDAHULUAN
Produksi sediaan steril harus dilakukan di ruang steril.
Ruang produksi harus memenuhi standar yang sesuai
dan dilengkapi dengan udara yang disterilkan melalui
filter khusus (HEPA filter)
Ruang steril untuk produksi sediaan steril
diklasifikasikan berdasarkan persyaratan lingkungan
yang diperlukan
Setiap kegiatan produksi memerlukan tingkatp g p g
sterilitas yang berbeda untuk meminimalkan resiko
kontaminasi partikulat dan mikroorganisme terhadap
produk atau bahan baku
4/18/2010
2
Maximum permitted number of particles /m3
Grade At rest In n operation
0.5mm 5mm 0.5mm 5mm
A 3500 0 3500 0
B 3500 0 350,000 2000
C 350,000 2,000 3,500,000 20,000
D 3,500,000 20,000 Not defined Not defined
4/18/2010
3
METODE PEMBUATAN SEDIAAN STERIL
STERILISASI AKHIR
STERILISASI DENGAN FILTARSI
ASEPTIK
PEMBUATAN SECARA ASEPTIK
4/18/2010
1
A ti P iAseptic Processing
Mrs Robyn Isaacson
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
1
Aseptic Processing - Overview
• Certain pharmaceutical products must be
sterile
injections ophthalmic preparations irrigations– injections, ophthalmic preparations, irrigations
solutions, haemodialysis solutions
• Two categories of sterile products
– those that can be sterilized in final container
(terminally sterilized)
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
2
( y )
– those that cannot be terminally sterilized and
must be aseptically prepared
4/18/2010
2
Aseptic Processing - Overview
Aseptic processing
• Objective is to maintain the sterility of a product,j y p ,
assembled from sterile components
• Operating conditions so as to prevent microbial
contamination
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
3
Aseptic Processing - Overview
Objective
• To review specific issues relating to the
manufacture of aseptically prepared products:p y p p p
– Manufacturing environment
• Clean areas
• Personnel
– Preparation and filtration of solutions
– Pre-filtration bioburden
– Filter integrity/validation
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
4
Filter integrity/validation
– Equipment/container preparation and sterilization
– Filling Process
– Validation of aseptic processes
– Specific issues relating to Isolators, BFS and Bulk
4/18/2010
3
Manufacturing Environment
Classification of Clean Areas
– Comparison of classifications
WHO GMP US 209E US Customary ISO/TC (209)
ISO 14644
EEC GMP
Grade A M 3.5 Class 100 ISO 5 Grade A
Grade B M 3.5 Class 100 ISO 5 Grade B
Grade C M 5.5 Class 10 000 ISO 7 Grade C
G d D M 6 5 Cl 100 000 ISO 8 G d D
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
5
Grade D M 6.5 Class 100 000 ISO 8 Grade D
Table 1
Manufacturing Environment
Classification of Clean Areas
– Classified in terms of airborne particles (Table 2)
Grade At rest In operationGrade At rest In operation
maximum permitted number of particles/m3
0.5 - 5.0 µm > 5 µm 0.5 - 5.0 µm > 5 µ
A 3 500 0 3 500 0
B 3 500 0 350 000 2 000
C 350 000 2 000 3 500 000 20 000
D 3 500 000 20 000 not defined not defined
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
6
“At rest” - production equipment installed and operating
“In operation” - Installed equipment functioning in defined
operating mode and specified number of personnel present
4/18/2010
4
Manufacturing Environment
Four grades of clean areas:
• Grade D (equivalent to Class 100,000, ISO 8):
– Clean area for carrying out less critical stages in
manufacture of aseptically prepared products eg.
handling of components after washing.
• Grade C (equivalent to Class 10,000, ISO 7):
– Clean area for carrying out less critical stages in
manufacture of aseptically prepared products eg.
preparation of solutions to be filtered.
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
7
p p
• Grade B (equivalent to Class 100, ISO 5):
– Background environment for Grade A zone, eg.
cleanroom in which laminar flow workstation is housed.
Manufacturing Environment
• Grade A (equivalent to Class 100 (US Federal
Standard 209E), ISO 5 (ISO 14644-1):
– Local zone for high risk operations eg. product filling,
t b l i l h dli t il t i lstopper bowls, open vials, handling sterile materials,
aseptic connections, transfer of partially stoppered
containers to be lyophilized.
– Conditions usually provided by laminar air flow
workstation.
• Each grade of cleanroom has specifications for
viable and non-viable particles
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
8
– Non-viable particles are defined by the air classification
(See Table 2)
4/18/2010
5
Manufacturing Environment
• Limits for viable particles (microbiological
contamination)
G d Ai l S ttl l t (90 C t t l t Gl i tGrade Air sample
(CFU/m3)
Settle plates (90mm
diameter)
(CFU/4hours)
Contact plates
(55mm
diameter)
(CFU/plate)
Glove print
(5 fingers)
(CFU/glove)
A < 3 < 3 < 3 < 3
B 10 5 5 5
C 100 50 25 -
D 200 100 50 -
Table 3
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
9
– These are average values
– Individual settle plates may be exposed for less than 4 hours
• Values are for guidance only - not intended to represent specifications
• Levels (limits) of detection of microbiological contamination should be
established for alert and action purposes and for monitoring trends of air
quality in the facility
Manufacturing Environment
Environmental Monitoring
• Physical
Particulate matter– Particulate matter
– Differential pressures
– Air changes, airflow patterns
– Clean up time/recovery
– Temperature and relative humidity
– Airflow velocity
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
10
4/18/2010
6
Manufacturing Environment
Environmental Monitoring - Physical
• Particulate matter
Particles significant because they can contaminate and– Particles significant because they can contaminate and
also carry organisms
– Critical environment should be measured not more than
30cm from worksite, within airflow and during
filling/closing operations
– Preferably a remote probe that monitors continuously
– Difficulties when process itself generates particles (e.g.
powder filling)
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
11
powder filling)
– Appropriate alert and action limits should be set and
corrective actions defined if limits exceeded
Manufacturing Environment
Environmental Monitoring - Physical
• Differential pressures
Positive pressure differential of 10-15 Pascals should be– Positive pressure differential of 10-15 Pascals should be
maintained between adjacent rooms of different
classification (with door closed)
– Most critical area should have the highest pressure
– Pressures should be continuously monitored and
frequently recorded.
– Alarms should sound if pressures deviate
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
12
– Any deviations should be investigated and effect on
environmental quality determined
4/18/2010
7
Manufacturing Environment
Environmental Monitoring - Physical
• Air Changes/Airflow patterns
Ai fl iti l h ld b i di ti l– Air flow over critical areas should be uni-directional
(laminar flow) at a velocity sufficient to sweep particles
away from filling/closing area
– for B, C and D rooms at least 20 changes per hour are
ususally required
• Clean up time/recovery
– Particulate levels for the Grade A “at rest” state should
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
13
be achieved after a short “clean-up” period of 20
minutes after completion of operations (guidance value)
– Particle counts for Grade A “in operation” state should
be maintained whenever product or open container is
exposed
Manufacturing Environment
Environmental Monitoring - Physical
• Temperature and Relative Humidity
Ambient temperature and humidity should not be– Ambient temperature and humidity should not be
uncomfortably high (could cause operators to
generate particles) (18°C)
• Airflow velocity
– Laminar airflow workstation air speed of approx
0.45m/s ± 20% at working position (guidance value)
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
14
4/18/2010
8
Manufacturing Environment
Personnel
• Minimum number of personnel in clean areas
– especially during aseptic processingp y g p p g
• Inspections and controls from outside
• Training to all including cleaning and
maintenance staff
– initial and regular
– manufacturing, hygiene, microbiology
– should be formally validated and authorized to enter
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
15
should be formally validated and authorized to enter
aseptic area
• Special cases
– supervision in case of outside staff
– decontamination procedures (e.g. staff who worked
with animal tissue materials)
Manufacturing Environment
Personnel (2)
• High standards of hygiene and cleanliness
– should not enter clean rooms if ill or with openshould not enter clean rooms if ill or with open
wounds
• Periodic health checks
• No shedding of particles, movement slow and
controlled
• No introduction of microbiological hazards
• No outdoor clothing brought into clean areas
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
16
No outdoor clothing brought into clean areas,
should be clad in factory clothing
• Changing and washing procedure
• No watches, jewellery and cosmetics
• Eye checks if involved in visual inspection
4/18/2010
9
Manufacturing Environment
Personnel (3)
• Clothing of appropriate quality:
– Grade D
• hair, beard, moustache covered
• protective clothing and shoes
– Grade C
• hair, beard, moustache covered
• single or 2-piece suit (covering wrists, high neck),
shoes/overshoes
• no fibres/particles to be shed
Grade A and B
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
17
– Grade A and B
• headgear, beard and moustache covered, masks,
gloves
• not shedding fibres, and retain particles shed by
operators
Manufacturing Environment
Personnel (4)
• Outdoor clothing not in change rooms leading to
G d B d CGrade B and C rooms
• Change at every working session, or once a day (if
supportive data)
• Change gloves and masks at every working session
• Frequent disinfection of gloves during operations
• Washing of garments – separate laundry facility
– No damage, and according to validated procedures
( hi d t ili ti )
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
18
(washing and sterilization)
• Regular microbiological monitoring of operators
4/18/2010
10
Aseptic Processing
• In aseptic processing, each component is
individually sterilised, or several components are
combined with the resulting mixture sterilized.
– Most common is preparation of a solution which is
filtered through a sterilizing filter then filled into sterile
containers (e.g active and excipients dissolved in Water
for Injection)
– May involve aseptic compounding of previously
sterilized components which is filled into sterile
containers
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
19
– May involve filling of previously sterilized powder
• sterilized by dry heat/irradiation
• produced from a sterile filtered solution which is then
aseptically crystallized and precipitated
– requires more handling and manipulation with higher
potential for contamination during processing
Aseptic Processing
Preparation and Filtration of Solutions
• Solutions to be sterile filtered prepared in a Grade C
environmentenvironment
• If not to be filtered, preparation should be prepared in
a Grade A environment with Grade B background (e.g.
ointments, creams, suspensions and emulsions)
• Prepared solutions filtered through a sterile 0.22µm
(or less) membrane filter into a previously sterilized
container
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
20
– filters remove bacteria and moulds
– do not remove all viruses or mycoplasmas
• filtration should be carried out under positive
pressure
4/18/2010
11
Aseptic Processing
Preparation and Filtration of Solutions (2)
• consideration should be given to complementing
filtration process with some form of heat treatmentfiltration process with some form of heat treatment
• Double filter or second filter at point of fill advisable
• Fitlers should not shed particles, asbestos containing
filters should not be used
• Same filter should not be used for more than one day
unless validated
• If bulk product is stored in sealed vessels pressure
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
21
• If bulk product is stored in sealed vessels, pressure
release outlets should have hydrophobic microbial
retentive air filters
Aseptic Processing
Preparation and Filtration of Solutions (3)
• Time limits should be established for each phase of
processing, e.g.processing, e.g.
– maximum period between start of bulk product
compounding and sterilization (filtration)
– maximum permitted holding time of bulk if held after
filtration prior to filling
– product exposure on processing line
– storage of sterilized containers/components
t t l ti f d t filt ti t t i
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
22
– total time for product filtration to prevent organisms
from penetrating filter
– maximum time for upstream filters used for clarification
or particle removal (can support microbial attachment)
4/18/2010
12
Aseptic Processing
Preparation and Filtration of Solutions (4)
• Filling of solution may be followed by lyophilization
(freeze drying)(freeze drying)
– stoppers partially seated, product transferred to
lyophilizer (Grade A/B conditions)
– Release of air/nitrogen into lyophilizer chamber at
completion of process should be through sterilizing
filter
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
23
Aseptic Processing
Prefiltration Bioburden (natural microbial load)
• Limits should be stated and testing should be carried
out on each batchout on each batch
• Frequency may be reduced after satisfactory history
is established
– and biobuden testing performed on components
• Should include action and alert limits (usually differ
by a factor of 10) and action taken if limits are
exceeded
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
24
• Limits should reasonably reflect bioburden routinely
achieved
4/18/2010
13
Aseptic Processing
Prefiltation Bioburden (2)
• No defined “maximum” limit but the limit should not
exceed the validated retention capability of the filter
• Bioburden controls should also be included in “in-
process” controls
– particularly when product supports microbial growth
and/or manufacturing process involves use of culture
media
• Excessive bioburden can have adverse effect on the
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
25
• Excessive bioburden can have adverse effect on the
quality of the product and cause excessive levels of
endotoxins/pyrogens
Aseptic Processing
Filter integrity
• Filters of 0.22µm or less should be used for filtration
of liquids and gasses (if applicable)of liquids and gasses (if applicable)
– filters for gasses that may be used for purging or
overlaying of filled containers or to release vacuum in
lyphilization chamber
• filter intergrity shoud be verified before filtration and
confirmed after filtration
– bubble point
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
26
– pressure hold
– forward flow
• methods are defined by filter manufacturers and limits
determined during filter validation
4/18/2010
14
Aseptic Processing
Filter Validaton
• Filter must be validated to demonstrate ability to
remove bacteriaremove bacteria
– most common method is to show that filter can retain a
microbiological challenge of 107 CFU of Brevundimonas
diminuta per cm2 of the filter surface
– a bioburden isolate may be more appropriate for filter
retention studies than Brevundimonas diminuta
– Challenge concentration is intended to provide a margin
f f
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
27
of safety well beyond what would be expected in
production
– preferably the microbial challenge is added to the fully
formulated product which is then passed through the
filter
Aseptic Processing
Filter validation (2)
– if the product is bactericidal, product should be passed
through the filter first followed by modified productthrough the filter first followed by modified product
containing the microbial challenge (after removing any
bactericidal activity remaining on the filter)
– filter validation should be carried out under worst case
conditions e.g. maximum allowed filtration time and
maximum pressure
– integrity testing specification for routine filtration
should correlate with that identified during filter
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
28
g
validation
4/18/2010
15
Aseptic Processing
Equipment/container preparation and
sterilization
• All equipment (including lyophilizers) and productq p ( g y p ) p
containers/closures should be sterilized using
validated cycles
– same requirements apply for equipment sterilization that
apply to terminally sterilized product
– particular attention to stoppers - should not be tightly
packed as may clump together and affect air removal
during vacuum stage of sterilization process
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
29
during vacuum stage of sterilization process
– equipment wrapped and loaded to facilitate air removal
– particular attention to filters, housings and tubing
Aseptic Processing
Equipment/container preparation and
sterilization (2)
• CIP/SIP processes
– particular attention to deadlegs - different orientation
requirements for CIP and SIP
• heat tunnels often used for
sterilization/depyrogenation of glass vials/bottles
– usually high temperature for short period of time
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
30
– need to consider speed of conveyor
– validation of depyrogenation (3 logs endotoxin units)
• worst case locations
– tunnel supplied with HEPA filtered air
4/18/2010
16
Aseptic Processing
Equipment/container preparation and
sterilization (2)
• equipment should be designed to be easily assembled and• equipment should be designed to be easily assembled and
disassembled, cleaned, sanitised and/or sterilized
– equipment should be appropriately cleaned - O-rings and
gaskets should be removed to prevent build up of dirt or
residues
• rinse water should be WFI grade
• equipment should be left dry unless sterilized immediately
after cleaning (to prevent build up of pyrogens)
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
31
g ( p p py g )
• washing of glass containers and rubber stoppers should be
validated for endotoxin removal
• should be defined storage period between sterilization and
use (period should be justified)
Aseptic Processing
Process Validation
• Not possible to define a sterility assurance level
for aseptic processingfor aseptic processing
• Process is validated by simulating the
manufacturing process using microbiological
growth medium (media fill)
– Process simulation includes formulation
(compounding), filtration and filling with suitable media
using the same processes involved in manufacture of
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
32
the product
– modifications must be made for different dosage
formats e.g. lyophilized products, ointments, sterile
bulks, eye drops filled into semi-transparent/opaque
containers, biological products
4/18/2010
17
Aseptic Processing
Process Validation (2)
• Media fill program should include worst case
activitiesactivities
– Factors associated with longest permitted run (e.g.
operator fatigue)
– Representative number, type, and complexity of
normal interventions, non-routine interventions
and events (e.g. maintenance, stoppages, etc)
– Lyophilisation
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
33
yop sat o
– Aseptic equipment assembly
Aseptic Processing
Process Validation (3)
• Worst case activities (cont)
No of personnel and their activities shift changes– No of personnel and their activities, shift changes,
breaks, gown changes
– Representative number of aseptic additions (e.g.
charging containers, closures, sterile ingredients)
or transfers
– Aseptic equipment connections/disconnections
– Aseptic sample collections
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
34
Aseptic sample collections
– Line speed and configuration
4/18/2010
18
Aseptic Processing
Process Validation (4)
• Worst case activities (cont)• Worst case activities (cont)
– Weight checks
– Container closure systems
– Specific provisions in processing instructions
• Written batch record documenting conditions and
activities
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
35
• Should not be used to justify risky practices
Aseptic Processing
Process Validation (5)
Duration
– Depends on type of operation
– BFS, Isolator processes - sufficient time to include
manipulations and interventions
– For conventional operations should include the total
filling time
Size
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
36
– 5000 - 10000 generally acceptable or batch size if <5000
– For manually intensive processes larger numbers
should be filled
– Lower numbers can be filled for isolators
4/18/2010
19
Aseptic Processing
Process Validation (6)
• Frequency and Number
Th i iti l ti hift– Three initial, consecutive per shift
– Subsequently semi-annual per shift and process
– All personnel should participate at least annually,
consistent with routine duties
– Changes should be assessed and revalidation
carried out as required
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
37
• Line Speed
– Speed depends on type of process
Aseptic Processing
Process Validation (7)
• Environmental conditions
– Representative of actual production conditions (no. of
personnel, activity levels etc) - no special precautions (not
including adjustment of HVAC)
– if nitrogen used for overlaying/purging need to substitute with
air
• Media
Anaerobic media should be considered under certain
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
38
– Anaerobic media should be considered under certain
circumstances
– Should be tested for growth promoting properties (including
factory isolates)
4/18/2010
20
Aseptic Processing
Process Validation (8)
• Incubation, Examination
In the range 20-35ºC– In the range 20-35 C.
– If two temperatures are used, lower temperature first
– Inspection by qualified personnel.
– All integral units should be incubated. Should be
justification for any units not incubated.
– Units removed (and not incubated) should be
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
39
Units removed (and not incubated) should be
consistent with routine practices (although
incubation would give information regarding risk of
intervention)
– Batch reconciliation
Aseptic Processing
Process Validation (9)
• Interpretation of Results
– When filling fewer than 5000 units:
• no contaminated units should be detected
• One (1) contaminated unit is considered cause for
revalidation, following an investigation
– When filling from 5000-10000 units
• One (1) contaminated unit should result in an
investigation, including consideration of a repeat media fill
• Two (2) contaminated units are considered cause for
lid ti f ll i i ti ti
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
40
revalidation, following investigation
– When filling more than 10000 units
• One (1) contaminated unit should result in an investigation
• Two (2) contaminated units are considered cause for
revalidation, following investigation
4/18/2010
21
Aseptic Processing
Process Validation (10)
• Interpretation of Results
– Media fills should be observed by QC and
contaminated units reconcilable with time and
activity being simulated (Video may help)
– Ideally - no contamination. Any contamination
should be investigated.
– Any organisms isolated should be identified to
species level (genotypic identification)
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
41
species level (genotypic identification)
– Invalidation of a media fill run should be rare
Aseptic Processing
Process Validation (11)
• Batch Record Review
– Process and environmental control activities
should be included in batch records and reviewed
as part of batch release
• In-process and laboratory control results
• Environmental and personnel monitoring data
• Output from support systems(HEPA/HVAC, WFI, steam
generator)
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
42
• Equipment function (batch alarm reports, filter integrity)
• Interventions, Deviations, Stoppages - duration and
associated time
• Written instructions regarding need for line clearances
• Disruptions to power supply
4/18/2010
22
Aseptic Processing
Additional issues specific to Isolator and
BFS Technologies
• Isolators• Isolators
– Decontamination process requires a 4-6 log
reduction of appropriate Biological Indicator (BI)
– Minimum 6 log reduction of BI if surface is to be
free of viable organisms
– Significant focus on glove integrity - daily checks,
second pair of gloves inside isolator glove
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
43
second pair of gloves inside isolator glove
– Traditional aseptic vigilance should be maintained
Aseptic Processing
• Blow-Fill-Seal (BFS)
– Located in a Grade D environment
– Critial zone should meet Grade A (microbiological)Critial zone should meet Grade A (microbiological)
requirements (particle count requirements may be
difficult to meet in operation)
– Operators meet Grade C garment requirements
– Validation of extrusion process should
demonstrate destruction of endotoxin and spore
challenges in the polymeric material
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
44
– Final inspection should be capable of detecting
leakers
4/18/2010
23
Aseptic Processing
• Issues relating to Aseptic Bulk Processing
• Applies to products which can not be filtered at point of
fill and require aseptic processing throughout entire
f t imanufacturing process.
• Entire aseptic process should be subject to process
simulation studies under worst case conditions
(maximum duration of "open" operations, maximum no
of operators)
• Process simulations should incorporate storage and
transport of bulk.
Multiple uses of the same bulk with storage in between
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
45
• Multiple uses of the same bulk with storage in between
should also be included in process simulations
• Assurance of bulk vessel integrity for specified holding
times.
Aseptic Processing
• Bulk Processing (2)
• Process simulation for formulation stage should be
performed at least twice per year.
– Cellular therapies, cell derived products etc
• products released before results of sterility tests
known (also TPNs, radioactive preps, cytotoxics)
• should be manufactured in a closed system
• Additional testing
– sterility testing of intermediates
microscopic examination (e g gram stain)
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
46
– microscopic examination (e.g. gram stain)
– endotoxin testing
4/18/2010
24
Useful Publications
• PIC/S Recommendation on the Validation of Aseptic
Processes
• FDA Guidance for Industry- Sterile Drug Products Produced
by Aseptic Processing Current Good Manufacturingby Aseptic Processing - Current Good Manufacturing
Process
• ISO 13408 Aseptic Processing of Health Care Products
– Part 1: General Requirements
– Part 2: Filtration
– Part 3: Lyophilization
– Part 4: Clean-In-Place Technologies
P S ili i I Pl
Manufacture of sterile medicines – Advanced workshop for SFDA GMP
inspectors - Nanjing, November 2009
47
– Part 5: Sterilization-In-Place
– Part 6: Isolator Systems
4/18/2010
4
MACAM SEDIAAN STERIL
1. Injeksi
Larutan obat dalam pembawa yang sesuai denganLarutan obat dalam pembawa yang sesuai dengan
atau tanpa zat tambahan, dimaksudkan untuk
pemberian secara parenteral
Dapat sebagai single dose dan multiple dose
2. Infus
Cairan yang diberikan melalui intravena: nutrisi
(dekstrosa) menjaga keseimbangan elektrolit (larutan(dekstrosa), menjaga keseimbangan elektrolit (larutan
ringer), untuk cairan pengganti (kombinasi dekstrosa
dan NaCl), dan untuk tujuan khusus (hiperalimentasi
parenteral)
3. Solid
Misalnya sediaan parenteral rekonstitusi
4. Suspensi
Ob t t i d l b i t kObat tersuspensi dalam pembawa yang sesuai untuk
parenteral .
5. Obat mata (larutan, suspensi, dan salep)
Khusus untuk salep mata, zat aktif baik dalam bentuk
terlarut atau serbuk tersuspensi halus dimasukkan ke
dalam basis salep yang non iritan. Salep disterilkan dengan
cara panas atau radiasi, dan sebagian dibuat dengan caracara panas atau rad as , dan sebag an d buat dengan cara
aseptik. Sediaan ini harus dikemas dalam wadah tertutup
dan bebas partikel logam.
4/18/2010
5
6. Larutan untuk irigasi
Larutan yang digunakan untuk mandi atau mencuci luka
terbuka.
Larutan di unakan secara t pikalLarutan digunakan secara topikal
METODE STERILISASI
Dalam bidang farmasi sterilisasi berarti destruksi sempurna
organisme hidup dan sporanya atau pemusnahan
mikroorganisme secara sempurna dari suatu sediaan
Ada 4 metode utama untuk sterilisasi produk farmasi:
1. Sterilisasi panas
- Basah sterilisasi uap
- Kering sterilisasi panas kering
2. Sterilisasi dengan cara filtrasi
3. Sterilisasi dengan gas
4 St ilis si d di si4. Sterilisasi dengan radiasi
Volume sediaan
Karakteristik sediaan (stabilitas)
Lolos uji sterilitas
4/18/2010
6
STERILISASI PANAS :
digunakan untuk membunuh mikroorganisme
Wet heat (otoklaf)/panas basah
Metode sterilisasi yang digunakan untukMetode sterilisasi yang digunakan untuk
destruksi semua mikroorganisme hidup
Dilakukan dalam otoklaf dengan menggunakan
panas pada suhu 121C dan uap jenuh dengan
tekanan 15 psi, selama 30-40 menit
Adanya uap menyebabkan protein
mikroorganisme terkoagulasi dan rusak pada
suhu yang lebih rendah dibandingkan jika tidaksuhu yang lebih rendah dibandingkan jika tidak
ada uap
APLIKASI STERILISASI UAP
UNTUK:
Semua sediaan dan bahan yang tahan terhadap panasSemua sediaan dan bahan yang tahan terhadap panas
pada suhu yang digunakan dan uap dapat berpenetrasi
sediaan larutan dalam kemasan, ruahan larutan, alat-
alat gelas, pakaian operasi dan peralatan operasi
TIDAK UNTUK:
Minyak, lemak, sediaan mengandung lemak, dan lain-lain
yang tidak bisa dipenetrasi oleh uap
Sediaan solid yang rusak oleh adanya lembap
4/18/2010
7
Faktor kritis yang mempengaruhi keberhasilan
sterilisasi:ster l sas
Suhu
Waktu sterilisasi
Kesempurnaan pergantian udara dengan uap
(tidak boleh ada udara yang terjerap)
Efektif terhadap semua jenis mikroorganismef f p j g
termasuk spora
Menguraikan asam nukleat, protein dan
membran
TEKANAN VS SUHU VS WAKTU
Tekanan Suhu Waktu
10 115.5 30
15 121.5 20
20 126.5 15
Tekanan suhu waktu
4/18/2010
8
STERILISASI PANAS KERING
Umumnya dilakukan di oven, baik dengan sistem pemanas gas
atau listrik dengan suhu terkontrol
Sterilisasi dengan cara panas kering kurang efisien
dibandingkan dengan cara basah sehingga:
Memerlukan waktu yang lebih lama (2-4 jam)
Memerlukan panas yang lebih tinggi (160-170C)
Suhu dan waktu bergantung pada:
Ukuran produk/sediaan
Jenis produk/sediaan
Jenis kemasan produk/sediaan
Karakteristik distribusi panas
Volume sekecil mungkin
Alat pensteril
mensirkulasi panas
secara bebas dan
menyeluruh
4/18/2010
9
APLIKASI STERILISASI PANAS KERING
Minyaky
Gliserin
Petrolatum
Parafin
Serbuk tahan panas (ZnO)
Alat-alat gelas
Perlengkapan operasi
STERILISASI FILTRASI
Penghilangan mikroorganisme dilakukan dengan
cara adsorpsi pada medium filter atau mekanismep p m m f m m
penapisan
Digunakan untuk produk atau bahan yang sensitif
terhadap panas, dan hanya untuk LARUTAN
Efektivitas sterilisasi dipengaruhi oleh jumlah
kandungan mikroba dalam larutan
4/18/2010
10
JENIS-JENIS FILTER
1. Filter berbentuk tabung reaksi filter candles,
terbuat dari mineral yang dikompres (Berkefeld
dan Mandler)dan Mandler)
2. Filter candles dari porselin (Pasteur-Chamberland,
Doulton, Selas)
3. Filter keping terbuat dari asbes yang dikompres
(Seitz dan Swinney)
4. Buchner
5. Millipore (terbaru)
FAKTOR PENTING DALAM FILTRASI
Uk i ( li ti )Ukuran pori (paling penting)
Muatan listrik filter dan mikroba
pH larutan
Suhu
TekananTekanan
4/18/2010
11
KEUNTUNGAN VS KERUGIAN METODE FILTRASI
Cepat (terutama untuk volum kecil)
M j t bilit d k/b h
KEUNTUNGAN
Menjaga stabilitas produk/bahan
Relatif murah
Sifat penghilangan mikroba dan partikulat lainnya
sempurna
KERUGIAN
Sifat adsorpsi zat tertentu (zat aktif) yang tidak
diinginkan terutama yang jumlahnya kecil
Terbatas penggunaannya untuk larutan-larutan viskus
STERILISASI GAS
Digunakan terutama untuk bahan yang tidak tahan
panas dan lembap
Bi s n dik mbin si den n t kl f: ut cl veBiasanya dikombinasi dengan otoklaf: autoclave-
ethylene oxide sterilizer dan perlu pertimbangan:
waktu, suhu, konsentrasi gas dan kelembapan:
Kelembapan sampai 60% dan suhu (50 dan 60C)
dapat t sterilisasi
Bahan yang tidak tahan lembap dan panasBahan yang tidak tahan lembap dan panas
memerlukan t sterilisasi lebih lama
Contoh gas pensteril: Etilen oksidandan propilen
oksida
4/18/2010
12
ETILEN OKSIDA
Sterilisasi dengan cara mengganggu metabolisme sel bakteri
Digunakan untuk sterilisasi produk yang tidak dapat
disterilkan dengan uapg p
Berupa gas tidak berwarna
Mudah terbakar dan meledak
Pemakaiannya terbatas
Keuntungan:
Dapat digunakan untuk sterilisasi bahan yang sensitif
terhadap panas dan lembap (perlengkapan operasi, senyawa
enzim, antibiotik) karena kemampuan penetrasinya yang baik
Kerugian:Kerugian:
Memerlukan waktu lama (4-16 jam)
Mahal
Berbahaya untuk pasien dan pekerja
Perlu pengecekan setelah sterilisasi untuk menjamin tidak
terjadinya reaksi kimia dan penguaraian pada bahan
Toksisitas metode sterilisasi dengan gas ETO
4/18/2010
13
STERILISASI DENGAN RADIASI
Sterilisasi menggunakan sinar gamma dan radiasi
katoda
Mekanisme kerja sterilisasi dengan radiasi belum
diketahui secara pasti, teori menyebutkan
terjadinya perubahan kimia destruktif pada mikroba
yang dapat merusak sel secara sempurna dan
ireversibel
RADIASI UV
Terbatas pada permukaan bahan karena UV tidak
dapat berpenetrasi ke dalam elas air lapisan dandapat berpenetrasi ke dalam gelas, air, lapisan dan
zat lain
Sudah digunakan untuk pengolahan air
4/18/2010
14
STERILISASI DENGAN PELARUT ORGANIK
Fenol
Alkohol
Formaldehid
4/18/2010
15
4/18/2010
16
NILAI F
Untuk mengkuantifikasi efektivitas proses sterilisasi
panas digunakan bilangan F (time of thermal death)
yaitu waktu yang diperlukan untuk membunuhyaitu waktu yang diperlukan untuk membunuh
organisme tertentu pada suatu kondisi
Nilai F dihitung dari data biologi yang diturunkan dari
kecepatan destruksi dari sejumlah mikroba, dengan
persamaan:
Fo = D121 (Log A – Log B)
A : populasi mikroba awal
B : jumlah mikroba yang hidup setelah waktu
pemanasan tertentu
PIROGEN DAN UJI PIROGEN
PIROGEN : senyawa organik yang dapat menimbulkan
demam berasal dari kontaminasi mikrobademam, berasal dari kontaminasi mikroba
Materi penyebabnya adalah LPS dari dinding luar sel
bakteri dan endotoksin
Pirogen termasuk senyawa yang termostabil sehingga
kemungkinan masih tertinggal dalam sediaan larutankemungkinan masih tertinggal dalam sediaan larutan
setelah proses sterilisasi dengan otoklaf maupun filtrasi
4/18/2010
17
PEMBEBASAN PIROGEN
DAN UJI PIROGEN
Pirogen (dalam air pro injeksi) dihilangkan dengan
adsorpsi menggunakan karbon aktif carip m gg f
prosedurnya!
Uji pirogen menurut USP dilakukan pada hewan
kelinci cari prosedurnya!
PENGEMBANGAN SEDIAAN STERIL
LIQUID SEMI SOLID SOLID
Suspensi
Emulsi
Larutan
bebas partikulat- bebas partikulat
- isotonis, terutama untuk volume besar dan intravena
- isohidris, idem (kapasitas dapar rendah)
- Bebas pirogen (terutama iv volume > 10 ml)
4/18/2010
18
OBAT SUNTIK
S di b l t l i t i d l iSediaan berupa larutan, emulsi atau suspensi dalam air
atau pembawa lain yang sesuai, steril dan digunakan
secara parenteral
Berdasarkan volumnya dibagi menjadi 2:
1. Volume kecil (berupa larutan atau suspensi, <10 ml)
2 Volume besar (berupa larutan >=100 ml diberikan2. Volume besar (berupa larutan >=100 ml, diberikan
sebagai infus intravena)
Contoh produk: “pharmaceutical dosage forms & dds”
LARGE VOLUME PARENTERAL (LVP)
Diberikan umumnya untuk penggantian cairan
tubuh, elektrolit atau nutrisi; terapi perawatan, ; p p w
paska operasi, pasien tidak sadar dan tidak bisa
menerima cairan, elektrolit dan nutrisi melalui
rute oral
Volume >= 100 ml per hari secara infus iv,
dengan atau tanpa kontrol kecepatan pemberian
Karena volumenya yang besar sediaan tidakKarena volumenya yang besar, sediaan tidak
boleh mengandung pengawet (bakteriostatik)
atau zat tambahan lain
Kemasan umumnya single dose
next: lihat “Pharmaceutical dosage forms & DDS”
4/18/2010
19
KLASIFIKASI OBAT SUNTIK
1. Bentuk sediaan
Larutan sejati pembawa air
Larutan sejati pembawa minyak
Larutan sejati pembawa pelarut campur
Suspensi steril pembawa air
Suspensi steril pembawa minyak
Serbuk rekonstitusi
Emulsi steril
2. Rute pemberian
Iv, im, sk, ik, ip, dan lain-lain, , , , p,
4/18/2010
20
BAHAN PEMBAWA OBAT SUNTIK
1. AIR
Ai i j k iAir pro injeksi
Aquabidest dengan pH tertentu, tidak mengandung
logam berat, tidak mengandung ion Ca, Cl, NO3,
SO4, Nh4, NO2 dan CO3
Harus steril, penggunaan dalam jumlah besar harus
bebas pirogen
Nilai tahanan spesifik sebesar 500.000 ohm/cm,
jik il i h k tid k b l h di kjika nilainya separuhnya maka tidak boleh digunakan
Aqua demineralisata tidak boleh digunakan sebagai
pembawa obat suntik
Air pro injeksi bebas CO2
Dibuat dengan cara mendidihkan air pro
injeksi selama 20-30 menit, lalu dialiri gas
N2 sambil didinginkan
Air pro injeksi bebas O2
Dibuat dengan cara mendidihkan air pro
injeksi selama 20-30 menit, jika dibutuhkan
dalam jumlah besar maka dialiri N2 sambil
didinginkandidinginkan
Digunakan untuk melarutkan zat aktif yang
mudah teroksidasi (klorpromazin,
prometazin, klorfeniramin, sulfamidin, dan
lain-lain)
4/18/2010
21
2. Non air
Digunakan jika:
Zat aktif tidak larut dalam pembawa air
k f d l bZat aktif terurai dalam pembawa air
Diinginkan kerja depo dari sediaan
Minyak tumbuhan
Mudah tengik karena mengandung asam lemak
bebas (+ antioksidan)
Tidak boleh mengandung minyak mineral atau
parafin cair karena tidak bisa dimetabolisme
dalam tubuh, karsinogenik, dan memberikan
reaksi terhadap jaringan
Sering menimbulkan rasa nyeri sehingga perlu
penambahan benzil alkohol 5% untuk anestesi
lokal
Jenis minyak tumbuhan yang digunakan:
Ol. Arachidis
Ol. SesamiOl. Sesami
Ol.Gossypii
Ol. Olivarum netral
Ol Terebintinae
Ol.Maidis
Ol.Amygdalarumyg
4/18/2010
22
Minyak semi sintesis
Ester asam lemak
AlkoholAlkohol
Memiliki aktivitas fisiologis, menimbulkan
rasa nyeri dan kerusakan jaringan pada
penggunaannya sehingga pemberiannya
secara iv tidak disarankan
FAKTOR YANG MEMPENGARUHI
ABSORPSI OBAT SUNTIK
Rute pemberian (iv > im > sk)Rute pemberian (iv > im > sk)
Ukuran partikel zat aktif (makin halus makin
cepat)
Polimorfisma (amorf > kristal)
Bentuk sediaan (larutan > emulsi > suspensi)
Pembawa (air > minyak)( y )
pH (untuk rute im dan sk isohidrisitas sangat
penting, iv tidak karena volume darah yang besar
dengan kapasitas dapar mampu menetralkan)
4/18/2010
23
TONISITAS LARUTAN
OBAT SUNTIK
ISOTONIS
Jika suatu larutan konsentrasinya sama dengan konsentrasiJika suatu larutan konsentrasinya sama dengan konsentrasi
dalam sel darah merah sehingga tidak terjadi pertukaran
cairan diantara keduanya
ISOOSMOTIK
Jika suatu larutan mempunyai tekanan osmotik yang sama
dengan tekanan osmotik serum
HIPOTONIS
Jika tekanan osmosis sediaan lebih rendah dari tekanan
osmosis serum darah, menyebabkan air akan melintasi
membran sel darah merah yang semipermeabel memperbesar
volume menyebabkan peningkatan tekanan dalam sel pecah
hemolisis
HIPERTONI
Jika tekanan osmosis sediaan lebih besar dari tekanan serum
darah, menyebabkan air keluar dari sel darah merah melintasi
membran semipermeabel mengakibatkan penciutan sel-sel
darah merah plasmolisism p m
TONISITAS MODIFIER
NaCl
Glukosa
Sukrosa
KNO3
NaNO3
4/18/2010
24
PERHITUNGAN ISOTONISITAS
“Pharmaceutical dosage form and drug delivery systems”

Weitere ähnliche Inhalte

Was ist angesagt?

Studi Kasus Drug Related Problems
Studi Kasus Drug Related ProblemsStudi Kasus Drug Related Problems
Studi Kasus Drug Related ProblemsMaulana Sakti
 
Registrasi Obat dan Produk Biologi
Registrasi Obat dan Produk BiologiRegistrasi Obat dan Produk Biologi
Registrasi Obat dan Produk Biologikhoiril anwar
 
Uji mutu sediaan kapsul
Uji mutu sediaan kapsul Uji mutu sediaan kapsul
Uji mutu sediaan kapsul DeLas Rac
 
Manajemen obat di rumah sakit
Manajemen obat di rumah sakitManajemen obat di rumah sakit
Manajemen obat di rumah sakitKANDA IZUL
 
Pedoman Interpretasi Data Klinik
Pedoman Interpretasi Data Klinik Pedoman Interpretasi Data Klinik
Pedoman Interpretasi Data Klinik Surya Amal
 
Mi 1 8. pemantauan dan evaluasi pengelolaan obat di puskesmas
Mi 1   8. pemantauan dan evaluasi pengelolaan obat di puskesmasMi 1   8. pemantauan dan evaluasi pengelolaan obat di puskesmas
Mi 1 8. pemantauan dan evaluasi pengelolaan obat di puskesmasLinaNadhilah2
 
Pengelolaan limbah industri farmasi
Pengelolaan limbah industri farmasiPengelolaan limbah industri farmasi
Pengelolaan limbah industri farmasihusnul khotimah
 
Kel 10. farmakoekonomi makalah-kualitas hidup
Kel 10. farmakoekonomi makalah-kualitas hidupKel 10. farmakoekonomi makalah-kualitas hidup
Kel 10. farmakoekonomi makalah-kualitas hidupAMIRRAHMATILLAH
 
Mi 1 6. pengendalian obat di puskesmas
Mi 1   6. pengendalian obat di puskesmasMi 1   6. pengendalian obat di puskesmas
Mi 1 6. pengendalian obat di puskesmasLinaNadhilah2
 
Evaluasi sediaan steril
Evaluasi sediaan sterilEvaluasi sediaan steril
Evaluasi sediaan sterilArwinAr
 
SISTEM DISTRIBUSI OBAT.pptx
SISTEM DISTRIBUSI OBAT.pptxSISTEM DISTRIBUSI OBAT.pptx
SISTEM DISTRIBUSI OBAT.pptxMrPharmacist247
 
272444618 beyond-used-date
272444618 beyond-used-date272444618 beyond-used-date
272444618 beyond-used-dateismayani arifin
 
Evaluasi Penggunaan Obat
Evaluasi Penggunaan ObatEvaluasi Penggunaan Obat
Evaluasi Penggunaan Obatsaninuraeni
 

Was ist angesagt? (20)

Studi Kasus Drug Related Problems
Studi Kasus Drug Related ProblemsStudi Kasus Drug Related Problems
Studi Kasus Drug Related Problems
 
Registrasi Obat dan Produk Biologi
Registrasi Obat dan Produk BiologiRegistrasi Obat dan Produk Biologi
Registrasi Obat dan Produk Biologi
 
Uji mutu sediaan kapsul
Uji mutu sediaan kapsul Uji mutu sediaan kapsul
Uji mutu sediaan kapsul
 
Manajemen obat di rumah sakit
Manajemen obat di rumah sakitManajemen obat di rumah sakit
Manajemen obat di rumah sakit
 
Pedoman Interpretasi Data Klinik
Pedoman Interpretasi Data Klinik Pedoman Interpretasi Data Klinik
Pedoman Interpretasi Data Klinik
 
Kasus 1
Kasus 1Kasus 1
Kasus 1
 
Qt.qld.08 (quy trình chuẩn bị, kiểm tra gmp)
Qt.qld.08 (quy trình chuẩn bị, kiểm tra gmp)Qt.qld.08 (quy trình chuẩn bị, kiểm tra gmp)
Qt.qld.08 (quy trình chuẩn bị, kiểm tra gmp)
 
Popp cpob jilid_1
Popp cpob jilid_1Popp cpob jilid_1
Popp cpob jilid_1
 
Mi 1 8. pemantauan dan evaluasi pengelolaan obat di puskesmas
Mi 1   8. pemantauan dan evaluasi pengelolaan obat di puskesmasMi 1   8. pemantauan dan evaluasi pengelolaan obat di puskesmas
Mi 1 8. pemantauan dan evaluasi pengelolaan obat di puskesmas
 
Pengelolaan limbah industri farmasi
Pengelolaan limbah industri farmasiPengelolaan limbah industri farmasi
Pengelolaan limbah industri farmasi
 
Kel 10. farmakoekonomi makalah-kualitas hidup
Kel 10. farmakoekonomi makalah-kualitas hidupKel 10. farmakoekonomi makalah-kualitas hidup
Kel 10. farmakoekonomi makalah-kualitas hidup
 
cpob (1).ppt
cpob (1).pptcpob (1).ppt
cpob (1).ppt
 
Mi 1 6. pengendalian obat di puskesmas
Mi 1   6. pengendalian obat di puskesmasMi 1   6. pengendalian obat di puskesmas
Mi 1 6. pengendalian obat di puskesmas
 
Evaluasi sediaan steril
Evaluasi sediaan sterilEvaluasi sediaan steril
Evaluasi sediaan steril
 
Cpob produksi
Cpob   produksiCpob   produksi
Cpob produksi
 
SISTEM DISTRIBUSI OBAT.pptx
SISTEM DISTRIBUSI OBAT.pptxSISTEM DISTRIBUSI OBAT.pptx
SISTEM DISTRIBUSI OBAT.pptx
 
272444618 beyond-used-date
272444618 beyond-used-date272444618 beyond-used-date
272444618 beyond-used-date
 
Evaluasi Penggunaan Obat
Evaluasi Penggunaan ObatEvaluasi Penggunaan Obat
Evaluasi Penggunaan Obat
 
Sistem HVAC
Sistem HVACSistem HVAC
Sistem HVAC
 
Uji sterilitas mikrobiologi
Uji sterilitas mikrobiologiUji sterilitas mikrobiologi
Uji sterilitas mikrobiologi
 

Andere mochten auch

Injeksi Thiamin HCL
Injeksi Thiamin HCLInjeksi Thiamin HCL
Injeksi Thiamin HCLRina Arina
 
Cari tentang sterilisasi dan macam
Cari tentang sterilisasi dan macamCari tentang sterilisasi dan macam
Cari tentang sterilisasi dan macamLucky Rima Simamora
 
Peraturan Kepala Badan POM tentang sertifikasi CPOB
Peraturan Kepala Badan POM tentang sertifikasi  CPOBPeraturan Kepala Badan POM tentang sertifikasi  CPOB
Peraturan Kepala Badan POM tentang sertifikasi CPOBBambang Priyambodo
 
Laporan Teknologi Sediaan Steril : Pembuatan Injeksi klorpromazin HCL.
Laporan Teknologi Sediaan Steril : Pembuatan Injeksi klorpromazin HCL.Laporan Teknologi Sediaan Steril : Pembuatan Injeksi klorpromazin HCL.
Laporan Teknologi Sediaan Steril : Pembuatan Injeksi klorpromazin HCL.Nova Rizky
 
Materi Injeksi untuk Perawat
Materi Injeksi untuk PerawatMateri Injeksi untuk Perawat
Materi Injeksi untuk Perawatarymita
 
Pengantar biokimia
Pengantar biokimiaPengantar biokimia
Pengantar biokimiaIzmoend Dy
 
Buku doen 2015
Buku doen 2015 Buku doen 2015
Buku doen 2015 hersu12345
 
Bab1 biokimia-pendahuluan
Bab1 biokimia-pendahuluanBab1 biokimia-pendahuluan
Bab1 biokimia-pendahuluanSendi Nomik
 

Andere mochten auch (14)

Kul1 course outline tfs. steril
Kul1 course outline tfs. sterilKul1 course outline tfs. steril
Kul1 course outline tfs. steril
 
226372818 injeksi
226372818 injeksi226372818 injeksi
226372818 injeksi
 
Injeksi Thiamin HCL
Injeksi Thiamin HCLInjeksi Thiamin HCL
Injeksi Thiamin HCL
 
Carbohydrate
CarbohydrateCarbohydrate
Carbohydrate
 
Cari tentang sterilisasi dan macam
Cari tentang sterilisasi dan macamCari tentang sterilisasi dan macam
Cari tentang sterilisasi dan macam
 
Peraturan Kepala Badan POM tentang sertifikasi CPOB
Peraturan Kepala Badan POM tentang sertifikasi  CPOBPeraturan Kepala Badan POM tentang sertifikasi  CPOB
Peraturan Kepala Badan POM tentang sertifikasi CPOB
 
Ppt biokimia
Ppt biokimiaPpt biokimia
Ppt biokimia
 
Laporan Teknologi Sediaan Steril : Pembuatan Injeksi klorpromazin HCL.
Laporan Teknologi Sediaan Steril : Pembuatan Injeksi klorpromazin HCL.Laporan Teknologi Sediaan Steril : Pembuatan Injeksi klorpromazin HCL.
Laporan Teknologi Sediaan Steril : Pembuatan Injeksi klorpromazin HCL.
 
Materi Injeksi untuk Perawat
Materi Injeksi untuk PerawatMateri Injeksi untuk Perawat
Materi Injeksi untuk Perawat
 
Pengantar biokimia
Pengantar biokimiaPengantar biokimia
Pengantar biokimia
 
Buku doen 2015
Buku doen 2015 Buku doen 2015
Buku doen 2015
 
Bentuk Sediaan Obat
Bentuk Sediaan ObatBentuk Sediaan Obat
Bentuk Sediaan Obat
 
Bab1 biokimia-pendahuluan
Bab1 biokimia-pendahuluanBab1 biokimia-pendahuluan
Bab1 biokimia-pendahuluan
 
Biokimia lipid
Biokimia lipidBiokimia lipid
Biokimia lipid
 

Ähnlich wie Sediaan steril [compatibility mode](1)

2-1_2-2_AsepticProcessing.ppt
2-1_2-2_AsepticProcessing.ppt2-1_2-2_AsepticProcessing.ppt
2-1_2-2_AsepticProcessing.pptbinhamid2
 
Sterile process validation
Sterile process validationSterile process validation
Sterile process validationSagar Savale
 
Aseptic Technique for sterile area .pptx
Aseptic Technique for sterile area .pptxAseptic Technique for sterile area .pptx
Aseptic Technique for sterile area .pptxNaeemSarwar37
 
Aseptic processing
Aseptic processingAseptic processing
Aseptic processingdeepakiitbhu
 
Aseptic processing
Aseptic processingAseptic processing
Aseptic processingdeepakiitbhu
 
STERILE PROCESS OF VALIDATION
STERILE PROCESS OF VALIDATIONSTERILE PROCESS OF VALIDATION
STERILE PROCESS OF VALIDATIONSagar Savale
 
Aseptic processing
Aseptic processingAseptic processing
Aseptic processingRiyaRYadav
 
Schedule M in pharmaceutical industries
Schedule M in pharmaceutical industries Schedule M in pharmaceutical industries
Schedule M in pharmaceutical industries rasika walunj
 
FDAs_GMP_Inspection_with_special_regard_to_Aseptic_Process_for_Drugs___Biolog...
FDAs_GMP_Inspection_with_special_regard_to_Aseptic_Process_for_Drugs___Biolog...FDAs_GMP_Inspection_with_special_regard_to_Aseptic_Process_for_Drugs___Biolog...
FDAs_GMP_Inspection_with_special_regard_to_Aseptic_Process_for_Drugs___Biolog...mmmmm624454
 
Environmental Characterization of Controlled Rooms
Environmental Characterization of Controlled RoomsEnvironmental Characterization of Controlled Rooms
Environmental Characterization of Controlled Roomsangelsalaman
 
Clean rooms in Injectables
Clean rooms in InjectablesClean rooms in Injectables
Clean rooms in InjectablesDr. Jigar Vyas
 
Sterilepharmaceuticalproduct
SterilepharmaceuticalproductSterilepharmaceuticalproduct
SterilepharmaceuticalproductMrs. Bhakti Mali
 
Facility requirements for Hazardous drug Manufacturing
Facility requirements for Hazardous drug  ManufacturingFacility requirements for Hazardous drug  Manufacturing
Facility requirements for Hazardous drug Manufacturingehab mohamed
 

Ähnlich wie Sediaan steril [compatibility mode](1) (20)

2-1_2-2_AsepticProcessing.ppt
2-1_2-2_AsepticProcessing.ppt2-1_2-2_AsepticProcessing.ppt
2-1_2-2_AsepticProcessing.ppt
 
WHO_Sterile Products.ppt
WHO_Sterile Products.pptWHO_Sterile Products.ppt
WHO_Sterile Products.ppt
 
Sterile process validation
Sterile process validationSterile process validation
Sterile process validation
 
Aseptic Technique for sterile area .pptx
Aseptic Technique for sterile area .pptxAseptic Technique for sterile area .pptx
Aseptic Technique for sterile area .pptx
 
Asepting procesing
Asepting procesingAsepting procesing
Asepting procesing
 
Aseptic processing
Aseptic processingAseptic processing
Aseptic processing
 
Aseptic processing
Aseptic processingAseptic processing
Aseptic processing
 
STERILE PROCESS OF VALIDATION
STERILE PROCESS OF VALIDATIONSTERILE PROCESS OF VALIDATION
STERILE PROCESS OF VALIDATION
 
Aseptic processing
Aseptic processingAseptic processing
Aseptic processing
 
Shedule m
Shedule mShedule m
Shedule m
 
Schedule M in pharmaceutical industries
Schedule M in pharmaceutical industries Schedule M in pharmaceutical industries
Schedule M in pharmaceutical industries
 
FDAs_GMP_Inspection_with_special_regard_to_Aseptic_Process_for_Drugs___Biolog...
FDAs_GMP_Inspection_with_special_regard_to_Aseptic_Process_for_Drugs___Biolog...FDAs_GMP_Inspection_with_special_regard_to_Aseptic_Process_for_Drugs___Biolog...
FDAs_GMP_Inspection_with_special_regard_to_Aseptic_Process_for_Drugs___Biolog...
 
Environmental Characterization of Controlled Rooms
Environmental Characterization of Controlled RoomsEnvironmental Characterization of Controlled Rooms
Environmental Characterization of Controlled Rooms
 
STERILE Prpn.pptx
STERILE Prpn.pptxSTERILE Prpn.pptx
STERILE Prpn.pptx
 
Environmental monitoring
Environmental monitoringEnvironmental monitoring
Environmental monitoring
 
Clean rooms in Injectables
Clean rooms in InjectablesClean rooms in Injectables
Clean rooms in Injectables
 
Manufacturing facility of parentarals as per schedule m
Manufacturing facility of parentarals as per schedule mManufacturing facility of parentarals as per schedule m
Manufacturing facility of parentarals as per schedule m
 
Gmp premicses
Gmp premicses Gmp premicses
Gmp premicses
 
Sterilepharmaceuticalproduct
SterilepharmaceuticalproductSterilepharmaceuticalproduct
Sterilepharmaceuticalproduct
 
Facility requirements for Hazardous drug Manufacturing
Facility requirements for Hazardous drug  ManufacturingFacility requirements for Hazardous drug  Manufacturing
Facility requirements for Hazardous drug Manufacturing
 

Mehr von Eka Selvina

Ipt 17 2005_p90_92x
Ipt 17 2005_p90_92xIpt 17 2005_p90_92x
Ipt 17 2005_p90_92xEka Selvina
 
Bioburden method validation
Bioburden method validationBioburden method validation
Bioburden method validationEka Selvina
 
79188922 cara-perhitungan-waktu-daluarsa
79188922 cara-perhitungan-waktu-daluarsa79188922 cara-perhitungan-waktu-daluarsa
79188922 cara-perhitungan-waktu-daluarsaEka Selvina
 
249456048 makalah-6-kimia-klinik-feses
249456048 makalah-6-kimia-klinik-feses249456048 makalah-6-kimia-klinik-feses
249456048 makalah-6-kimia-klinik-fesesEka Selvina
 
126996728 darah-samar-frida
126996728 darah-samar-frida126996728 darah-samar-frida
126996728 darah-samar-fridaEka Selvina
 
Disinfectants and sterilization methods. rev.09302013
Disinfectants and sterilization methods. rev.09302013Disinfectants and sterilization methods. rev.09302013
Disinfectants and sterilization methods. rev.09302013Eka Selvina
 

Mehr von Eka Selvina (13)

Ipt 17 2005_p90_92x
Ipt 17 2005_p90_92xIpt 17 2005_p90_92x
Ipt 17 2005_p90_92x
 
Bioburden method validation
Bioburden method validationBioburden method validation
Bioburden method validation
 
Mb usp 797
Mb usp 797Mb usp 797
Mb usp 797
 
Cmc2
Cmc2Cmc2
Cmc2
 
Article 98050
Article 98050Article 98050
Article 98050
 
79188922 cara-perhitungan-waktu-daluarsa
79188922 cara-perhitungan-waktu-daluarsa79188922 cara-perhitungan-waktu-daluarsa
79188922 cara-perhitungan-waktu-daluarsa
 
249456048 makalah-6-kimia-klinik-feses
249456048 makalah-6-kimia-klinik-feses249456048 makalah-6-kimia-klinik-feses
249456048 makalah-6-kimia-klinik-feses
 
126996728 darah-samar-frida
126996728 darah-samar-frida126996728 darah-samar-frida
126996728 darah-samar-frida
 
Disinfectants and sterilization methods. rev.09302013
Disinfectants and sterilization methods. rev.09302013Disinfectants and sterilization methods. rev.09302013
Disinfectants and sterilization methods. rev.09302013
 
Daftar pustaka
Daftar pustakaDaftar pustaka
Daftar pustaka
 
A 3
A 3A 3
A 3
 
A 2
A 2A 2
A 2
 
A 1
A 1A 1
A 1
 

Sediaan steril [compatibility mode](1)

  • 1. 4/18/2010 1 SEDIAAN STERIL Dr.Heni Rachmawati SCHOOL OF PHARMACY - ITB PENDAHULUAN Produksi sediaan steril harus dilakukan di ruang steril. Ruang produksi harus memenuhi standar yang sesuai dan dilengkapi dengan udara yang disterilkan melalui filter khusus (HEPA filter) Ruang steril untuk produksi sediaan steril diklasifikasikan berdasarkan persyaratan lingkungan yang diperlukan Setiap kegiatan produksi memerlukan tingkatp g p g sterilitas yang berbeda untuk meminimalkan resiko kontaminasi partikulat dan mikroorganisme terhadap produk atau bahan baku
  • 2. 4/18/2010 2 Maximum permitted number of particles /m3 Grade At rest In n operation 0.5mm 5mm 0.5mm 5mm A 3500 0 3500 0 B 3500 0 350,000 2000 C 350,000 2,000 3,500,000 20,000 D 3,500,000 20,000 Not defined Not defined
  • 3. 4/18/2010 3 METODE PEMBUATAN SEDIAAN STERIL STERILISASI AKHIR STERILISASI DENGAN FILTARSI ASEPTIK PEMBUATAN SECARA ASEPTIK
  • 4. 4/18/2010 1 A ti P iAseptic Processing Mrs Robyn Isaacson Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 1 Aseptic Processing - Overview • Certain pharmaceutical products must be sterile injections ophthalmic preparations irrigations– injections, ophthalmic preparations, irrigations solutions, haemodialysis solutions • Two categories of sterile products – those that can be sterilized in final container (terminally sterilized) Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 2 ( y ) – those that cannot be terminally sterilized and must be aseptically prepared
  • 5. 4/18/2010 2 Aseptic Processing - Overview Aseptic processing • Objective is to maintain the sterility of a product,j y p , assembled from sterile components • Operating conditions so as to prevent microbial contamination Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 3 Aseptic Processing - Overview Objective • To review specific issues relating to the manufacture of aseptically prepared products:p y p p p – Manufacturing environment • Clean areas • Personnel – Preparation and filtration of solutions – Pre-filtration bioburden – Filter integrity/validation Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 4 Filter integrity/validation – Equipment/container preparation and sterilization – Filling Process – Validation of aseptic processes – Specific issues relating to Isolators, BFS and Bulk
  • 6. 4/18/2010 3 Manufacturing Environment Classification of Clean Areas – Comparison of classifications WHO GMP US 209E US Customary ISO/TC (209) ISO 14644 EEC GMP Grade A M 3.5 Class 100 ISO 5 Grade A Grade B M 3.5 Class 100 ISO 5 Grade B Grade C M 5.5 Class 10 000 ISO 7 Grade C G d D M 6 5 Cl 100 000 ISO 8 G d D Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 5 Grade D M 6.5 Class 100 000 ISO 8 Grade D Table 1 Manufacturing Environment Classification of Clean Areas – Classified in terms of airborne particles (Table 2) Grade At rest In operationGrade At rest In operation maximum permitted number of particles/m3 0.5 - 5.0 µm > 5 µm 0.5 - 5.0 µm > 5 µ A 3 500 0 3 500 0 B 3 500 0 350 000 2 000 C 350 000 2 000 3 500 000 20 000 D 3 500 000 20 000 not defined not defined Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 6 “At rest” - production equipment installed and operating “In operation” - Installed equipment functioning in defined operating mode and specified number of personnel present
  • 7. 4/18/2010 4 Manufacturing Environment Four grades of clean areas: • Grade D (equivalent to Class 100,000, ISO 8): – Clean area for carrying out less critical stages in manufacture of aseptically prepared products eg. handling of components after washing. • Grade C (equivalent to Class 10,000, ISO 7): – Clean area for carrying out less critical stages in manufacture of aseptically prepared products eg. preparation of solutions to be filtered. Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 7 p p • Grade B (equivalent to Class 100, ISO 5): – Background environment for Grade A zone, eg. cleanroom in which laminar flow workstation is housed. Manufacturing Environment • Grade A (equivalent to Class 100 (US Federal Standard 209E), ISO 5 (ISO 14644-1): – Local zone for high risk operations eg. product filling, t b l i l h dli t il t i lstopper bowls, open vials, handling sterile materials, aseptic connections, transfer of partially stoppered containers to be lyophilized. – Conditions usually provided by laminar air flow workstation. • Each grade of cleanroom has specifications for viable and non-viable particles Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 8 – Non-viable particles are defined by the air classification (See Table 2)
  • 8. 4/18/2010 5 Manufacturing Environment • Limits for viable particles (microbiological contamination) G d Ai l S ttl l t (90 C t t l t Gl i tGrade Air sample (CFU/m3) Settle plates (90mm diameter) (CFU/4hours) Contact plates (55mm diameter) (CFU/plate) Glove print (5 fingers) (CFU/glove) A < 3 < 3 < 3 < 3 B 10 5 5 5 C 100 50 25 - D 200 100 50 - Table 3 Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 9 – These are average values – Individual settle plates may be exposed for less than 4 hours • Values are for guidance only - not intended to represent specifications • Levels (limits) of detection of microbiological contamination should be established for alert and action purposes and for monitoring trends of air quality in the facility Manufacturing Environment Environmental Monitoring • Physical Particulate matter– Particulate matter – Differential pressures – Air changes, airflow patterns – Clean up time/recovery – Temperature and relative humidity – Airflow velocity Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 10
  • 9. 4/18/2010 6 Manufacturing Environment Environmental Monitoring - Physical • Particulate matter Particles significant because they can contaminate and– Particles significant because they can contaminate and also carry organisms – Critical environment should be measured not more than 30cm from worksite, within airflow and during filling/closing operations – Preferably a remote probe that monitors continuously – Difficulties when process itself generates particles (e.g. powder filling) Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 11 powder filling) – Appropriate alert and action limits should be set and corrective actions defined if limits exceeded Manufacturing Environment Environmental Monitoring - Physical • Differential pressures Positive pressure differential of 10-15 Pascals should be– Positive pressure differential of 10-15 Pascals should be maintained between adjacent rooms of different classification (with door closed) – Most critical area should have the highest pressure – Pressures should be continuously monitored and frequently recorded. – Alarms should sound if pressures deviate Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 12 – Any deviations should be investigated and effect on environmental quality determined
  • 10. 4/18/2010 7 Manufacturing Environment Environmental Monitoring - Physical • Air Changes/Airflow patterns Ai fl iti l h ld b i di ti l– Air flow over critical areas should be uni-directional (laminar flow) at a velocity sufficient to sweep particles away from filling/closing area – for B, C and D rooms at least 20 changes per hour are ususally required • Clean up time/recovery – Particulate levels for the Grade A “at rest” state should Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 13 be achieved after a short “clean-up” period of 20 minutes after completion of operations (guidance value) – Particle counts for Grade A “in operation” state should be maintained whenever product or open container is exposed Manufacturing Environment Environmental Monitoring - Physical • Temperature and Relative Humidity Ambient temperature and humidity should not be– Ambient temperature and humidity should not be uncomfortably high (could cause operators to generate particles) (18°C) • Airflow velocity – Laminar airflow workstation air speed of approx 0.45m/s ± 20% at working position (guidance value) Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 14
  • 11. 4/18/2010 8 Manufacturing Environment Personnel • Minimum number of personnel in clean areas – especially during aseptic processingp y g p p g • Inspections and controls from outside • Training to all including cleaning and maintenance staff – initial and regular – manufacturing, hygiene, microbiology – should be formally validated and authorized to enter Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 15 should be formally validated and authorized to enter aseptic area • Special cases – supervision in case of outside staff – decontamination procedures (e.g. staff who worked with animal tissue materials) Manufacturing Environment Personnel (2) • High standards of hygiene and cleanliness – should not enter clean rooms if ill or with openshould not enter clean rooms if ill or with open wounds • Periodic health checks • No shedding of particles, movement slow and controlled • No introduction of microbiological hazards • No outdoor clothing brought into clean areas Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 16 No outdoor clothing brought into clean areas, should be clad in factory clothing • Changing and washing procedure • No watches, jewellery and cosmetics • Eye checks if involved in visual inspection
  • 12. 4/18/2010 9 Manufacturing Environment Personnel (3) • Clothing of appropriate quality: – Grade D • hair, beard, moustache covered • protective clothing and shoes – Grade C • hair, beard, moustache covered • single or 2-piece suit (covering wrists, high neck), shoes/overshoes • no fibres/particles to be shed Grade A and B Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 17 – Grade A and B • headgear, beard and moustache covered, masks, gloves • not shedding fibres, and retain particles shed by operators Manufacturing Environment Personnel (4) • Outdoor clothing not in change rooms leading to G d B d CGrade B and C rooms • Change at every working session, or once a day (if supportive data) • Change gloves and masks at every working session • Frequent disinfection of gloves during operations • Washing of garments – separate laundry facility – No damage, and according to validated procedures ( hi d t ili ti ) Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 18 (washing and sterilization) • Regular microbiological monitoring of operators
  • 13. 4/18/2010 10 Aseptic Processing • In aseptic processing, each component is individually sterilised, or several components are combined with the resulting mixture sterilized. – Most common is preparation of a solution which is filtered through a sterilizing filter then filled into sterile containers (e.g active and excipients dissolved in Water for Injection) – May involve aseptic compounding of previously sterilized components which is filled into sterile containers Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 19 – May involve filling of previously sterilized powder • sterilized by dry heat/irradiation • produced from a sterile filtered solution which is then aseptically crystallized and precipitated – requires more handling and manipulation with higher potential for contamination during processing Aseptic Processing Preparation and Filtration of Solutions • Solutions to be sterile filtered prepared in a Grade C environmentenvironment • If not to be filtered, preparation should be prepared in a Grade A environment with Grade B background (e.g. ointments, creams, suspensions and emulsions) • Prepared solutions filtered through a sterile 0.22µm (or less) membrane filter into a previously sterilized container Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 20 – filters remove bacteria and moulds – do not remove all viruses or mycoplasmas • filtration should be carried out under positive pressure
  • 14. 4/18/2010 11 Aseptic Processing Preparation and Filtration of Solutions (2) • consideration should be given to complementing filtration process with some form of heat treatmentfiltration process with some form of heat treatment • Double filter or second filter at point of fill advisable • Fitlers should not shed particles, asbestos containing filters should not be used • Same filter should not be used for more than one day unless validated • If bulk product is stored in sealed vessels pressure Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 21 • If bulk product is stored in sealed vessels, pressure release outlets should have hydrophobic microbial retentive air filters Aseptic Processing Preparation and Filtration of Solutions (3) • Time limits should be established for each phase of processing, e.g.processing, e.g. – maximum period between start of bulk product compounding and sterilization (filtration) – maximum permitted holding time of bulk if held after filtration prior to filling – product exposure on processing line – storage of sterilized containers/components t t l ti f d t filt ti t t i Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 22 – total time for product filtration to prevent organisms from penetrating filter – maximum time for upstream filters used for clarification or particle removal (can support microbial attachment)
  • 15. 4/18/2010 12 Aseptic Processing Preparation and Filtration of Solutions (4) • Filling of solution may be followed by lyophilization (freeze drying)(freeze drying) – stoppers partially seated, product transferred to lyophilizer (Grade A/B conditions) – Release of air/nitrogen into lyophilizer chamber at completion of process should be through sterilizing filter Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 23 Aseptic Processing Prefiltration Bioburden (natural microbial load) • Limits should be stated and testing should be carried out on each batchout on each batch • Frequency may be reduced after satisfactory history is established – and biobuden testing performed on components • Should include action and alert limits (usually differ by a factor of 10) and action taken if limits are exceeded Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 24 • Limits should reasonably reflect bioburden routinely achieved
  • 16. 4/18/2010 13 Aseptic Processing Prefiltation Bioburden (2) • No defined “maximum” limit but the limit should not exceed the validated retention capability of the filter • Bioburden controls should also be included in “in- process” controls – particularly when product supports microbial growth and/or manufacturing process involves use of culture media • Excessive bioburden can have adverse effect on the Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 25 • Excessive bioburden can have adverse effect on the quality of the product and cause excessive levels of endotoxins/pyrogens Aseptic Processing Filter integrity • Filters of 0.22µm or less should be used for filtration of liquids and gasses (if applicable)of liquids and gasses (if applicable) – filters for gasses that may be used for purging or overlaying of filled containers or to release vacuum in lyphilization chamber • filter intergrity shoud be verified before filtration and confirmed after filtration – bubble point Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 26 – pressure hold – forward flow • methods are defined by filter manufacturers and limits determined during filter validation
  • 17. 4/18/2010 14 Aseptic Processing Filter Validaton • Filter must be validated to demonstrate ability to remove bacteriaremove bacteria – most common method is to show that filter can retain a microbiological challenge of 107 CFU of Brevundimonas diminuta per cm2 of the filter surface – a bioburden isolate may be more appropriate for filter retention studies than Brevundimonas diminuta – Challenge concentration is intended to provide a margin f f Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 27 of safety well beyond what would be expected in production – preferably the microbial challenge is added to the fully formulated product which is then passed through the filter Aseptic Processing Filter validation (2) – if the product is bactericidal, product should be passed through the filter first followed by modified productthrough the filter first followed by modified product containing the microbial challenge (after removing any bactericidal activity remaining on the filter) – filter validation should be carried out under worst case conditions e.g. maximum allowed filtration time and maximum pressure – integrity testing specification for routine filtration should correlate with that identified during filter Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 28 g validation
  • 18. 4/18/2010 15 Aseptic Processing Equipment/container preparation and sterilization • All equipment (including lyophilizers) and productq p ( g y p ) p containers/closures should be sterilized using validated cycles – same requirements apply for equipment sterilization that apply to terminally sterilized product – particular attention to stoppers - should not be tightly packed as may clump together and affect air removal during vacuum stage of sterilization process Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 29 during vacuum stage of sterilization process – equipment wrapped and loaded to facilitate air removal – particular attention to filters, housings and tubing Aseptic Processing Equipment/container preparation and sterilization (2) • CIP/SIP processes – particular attention to deadlegs - different orientation requirements for CIP and SIP • heat tunnels often used for sterilization/depyrogenation of glass vials/bottles – usually high temperature for short period of time Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 30 – need to consider speed of conveyor – validation of depyrogenation (3 logs endotoxin units) • worst case locations – tunnel supplied with HEPA filtered air
  • 19. 4/18/2010 16 Aseptic Processing Equipment/container preparation and sterilization (2) • equipment should be designed to be easily assembled and• equipment should be designed to be easily assembled and disassembled, cleaned, sanitised and/or sterilized – equipment should be appropriately cleaned - O-rings and gaskets should be removed to prevent build up of dirt or residues • rinse water should be WFI grade • equipment should be left dry unless sterilized immediately after cleaning (to prevent build up of pyrogens) Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 31 g ( p p py g ) • washing of glass containers and rubber stoppers should be validated for endotoxin removal • should be defined storage period between sterilization and use (period should be justified) Aseptic Processing Process Validation • Not possible to define a sterility assurance level for aseptic processingfor aseptic processing • Process is validated by simulating the manufacturing process using microbiological growth medium (media fill) – Process simulation includes formulation (compounding), filtration and filling with suitable media using the same processes involved in manufacture of Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 32 the product – modifications must be made for different dosage formats e.g. lyophilized products, ointments, sterile bulks, eye drops filled into semi-transparent/opaque containers, biological products
  • 20. 4/18/2010 17 Aseptic Processing Process Validation (2) • Media fill program should include worst case activitiesactivities – Factors associated with longest permitted run (e.g. operator fatigue) – Representative number, type, and complexity of normal interventions, non-routine interventions and events (e.g. maintenance, stoppages, etc) – Lyophilisation Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 33 yop sat o – Aseptic equipment assembly Aseptic Processing Process Validation (3) • Worst case activities (cont) No of personnel and their activities shift changes– No of personnel and their activities, shift changes, breaks, gown changes – Representative number of aseptic additions (e.g. charging containers, closures, sterile ingredients) or transfers – Aseptic equipment connections/disconnections – Aseptic sample collections Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 34 Aseptic sample collections – Line speed and configuration
  • 21. 4/18/2010 18 Aseptic Processing Process Validation (4) • Worst case activities (cont)• Worst case activities (cont) – Weight checks – Container closure systems – Specific provisions in processing instructions • Written batch record documenting conditions and activities Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 35 • Should not be used to justify risky practices Aseptic Processing Process Validation (5) Duration – Depends on type of operation – BFS, Isolator processes - sufficient time to include manipulations and interventions – For conventional operations should include the total filling time Size Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 36 – 5000 - 10000 generally acceptable or batch size if <5000 – For manually intensive processes larger numbers should be filled – Lower numbers can be filled for isolators
  • 22. 4/18/2010 19 Aseptic Processing Process Validation (6) • Frequency and Number Th i iti l ti hift– Three initial, consecutive per shift – Subsequently semi-annual per shift and process – All personnel should participate at least annually, consistent with routine duties – Changes should be assessed and revalidation carried out as required Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 37 • Line Speed – Speed depends on type of process Aseptic Processing Process Validation (7) • Environmental conditions – Representative of actual production conditions (no. of personnel, activity levels etc) - no special precautions (not including adjustment of HVAC) – if nitrogen used for overlaying/purging need to substitute with air • Media Anaerobic media should be considered under certain Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 38 – Anaerobic media should be considered under certain circumstances – Should be tested for growth promoting properties (including factory isolates)
  • 23. 4/18/2010 20 Aseptic Processing Process Validation (8) • Incubation, Examination In the range 20-35ºC– In the range 20-35 C. – If two temperatures are used, lower temperature first – Inspection by qualified personnel. – All integral units should be incubated. Should be justification for any units not incubated. – Units removed (and not incubated) should be Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 39 Units removed (and not incubated) should be consistent with routine practices (although incubation would give information regarding risk of intervention) – Batch reconciliation Aseptic Processing Process Validation (9) • Interpretation of Results – When filling fewer than 5000 units: • no contaminated units should be detected • One (1) contaminated unit is considered cause for revalidation, following an investigation – When filling from 5000-10000 units • One (1) contaminated unit should result in an investigation, including consideration of a repeat media fill • Two (2) contaminated units are considered cause for lid ti f ll i i ti ti Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 40 revalidation, following investigation – When filling more than 10000 units • One (1) contaminated unit should result in an investigation • Two (2) contaminated units are considered cause for revalidation, following investigation
  • 24. 4/18/2010 21 Aseptic Processing Process Validation (10) • Interpretation of Results – Media fills should be observed by QC and contaminated units reconcilable with time and activity being simulated (Video may help) – Ideally - no contamination. Any contamination should be investigated. – Any organisms isolated should be identified to species level (genotypic identification) Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 41 species level (genotypic identification) – Invalidation of a media fill run should be rare Aseptic Processing Process Validation (11) • Batch Record Review – Process and environmental control activities should be included in batch records and reviewed as part of batch release • In-process and laboratory control results • Environmental and personnel monitoring data • Output from support systems(HEPA/HVAC, WFI, steam generator) Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 42 • Equipment function (batch alarm reports, filter integrity) • Interventions, Deviations, Stoppages - duration and associated time • Written instructions regarding need for line clearances • Disruptions to power supply
  • 25. 4/18/2010 22 Aseptic Processing Additional issues specific to Isolator and BFS Technologies • Isolators• Isolators – Decontamination process requires a 4-6 log reduction of appropriate Biological Indicator (BI) – Minimum 6 log reduction of BI if surface is to be free of viable organisms – Significant focus on glove integrity - daily checks, second pair of gloves inside isolator glove Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 43 second pair of gloves inside isolator glove – Traditional aseptic vigilance should be maintained Aseptic Processing • Blow-Fill-Seal (BFS) – Located in a Grade D environment – Critial zone should meet Grade A (microbiological)Critial zone should meet Grade A (microbiological) requirements (particle count requirements may be difficult to meet in operation) – Operators meet Grade C garment requirements – Validation of extrusion process should demonstrate destruction of endotoxin and spore challenges in the polymeric material Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 44 – Final inspection should be capable of detecting leakers
  • 26. 4/18/2010 23 Aseptic Processing • Issues relating to Aseptic Bulk Processing • Applies to products which can not be filtered at point of fill and require aseptic processing throughout entire f t imanufacturing process. • Entire aseptic process should be subject to process simulation studies under worst case conditions (maximum duration of "open" operations, maximum no of operators) • Process simulations should incorporate storage and transport of bulk. Multiple uses of the same bulk with storage in between Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 45 • Multiple uses of the same bulk with storage in between should also be included in process simulations • Assurance of bulk vessel integrity for specified holding times. Aseptic Processing • Bulk Processing (2) • Process simulation for formulation stage should be performed at least twice per year. – Cellular therapies, cell derived products etc • products released before results of sterility tests known (also TPNs, radioactive preps, cytotoxics) • should be manufactured in a closed system • Additional testing – sterility testing of intermediates microscopic examination (e g gram stain) Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 46 – microscopic examination (e.g. gram stain) – endotoxin testing
  • 27. 4/18/2010 24 Useful Publications • PIC/S Recommendation on the Validation of Aseptic Processes • FDA Guidance for Industry- Sterile Drug Products Produced by Aseptic Processing Current Good Manufacturingby Aseptic Processing - Current Good Manufacturing Process • ISO 13408 Aseptic Processing of Health Care Products – Part 1: General Requirements – Part 2: Filtration – Part 3: Lyophilization – Part 4: Clean-In-Place Technologies P S ili i I Pl Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors - Nanjing, November 2009 47 – Part 5: Sterilization-In-Place – Part 6: Isolator Systems
  • 28. 4/18/2010 4 MACAM SEDIAAN STERIL 1. Injeksi Larutan obat dalam pembawa yang sesuai denganLarutan obat dalam pembawa yang sesuai dengan atau tanpa zat tambahan, dimaksudkan untuk pemberian secara parenteral Dapat sebagai single dose dan multiple dose 2. Infus Cairan yang diberikan melalui intravena: nutrisi (dekstrosa) menjaga keseimbangan elektrolit (larutan(dekstrosa), menjaga keseimbangan elektrolit (larutan ringer), untuk cairan pengganti (kombinasi dekstrosa dan NaCl), dan untuk tujuan khusus (hiperalimentasi parenteral) 3. Solid Misalnya sediaan parenteral rekonstitusi 4. Suspensi Ob t t i d l b i t kObat tersuspensi dalam pembawa yang sesuai untuk parenteral . 5. Obat mata (larutan, suspensi, dan salep) Khusus untuk salep mata, zat aktif baik dalam bentuk terlarut atau serbuk tersuspensi halus dimasukkan ke dalam basis salep yang non iritan. Salep disterilkan dengan cara panas atau radiasi, dan sebagian dibuat dengan caracara panas atau rad as , dan sebag an d buat dengan cara aseptik. Sediaan ini harus dikemas dalam wadah tertutup dan bebas partikel logam.
  • 29. 4/18/2010 5 6. Larutan untuk irigasi Larutan yang digunakan untuk mandi atau mencuci luka terbuka. Larutan di unakan secara t pikalLarutan digunakan secara topikal METODE STERILISASI Dalam bidang farmasi sterilisasi berarti destruksi sempurna organisme hidup dan sporanya atau pemusnahan mikroorganisme secara sempurna dari suatu sediaan Ada 4 metode utama untuk sterilisasi produk farmasi: 1. Sterilisasi panas - Basah sterilisasi uap - Kering sterilisasi panas kering 2. Sterilisasi dengan cara filtrasi 3. Sterilisasi dengan gas 4 St ilis si d di si4. Sterilisasi dengan radiasi Volume sediaan Karakteristik sediaan (stabilitas) Lolos uji sterilitas
  • 30. 4/18/2010 6 STERILISASI PANAS : digunakan untuk membunuh mikroorganisme Wet heat (otoklaf)/panas basah Metode sterilisasi yang digunakan untukMetode sterilisasi yang digunakan untuk destruksi semua mikroorganisme hidup Dilakukan dalam otoklaf dengan menggunakan panas pada suhu 121C dan uap jenuh dengan tekanan 15 psi, selama 30-40 menit Adanya uap menyebabkan protein mikroorganisme terkoagulasi dan rusak pada suhu yang lebih rendah dibandingkan jika tidaksuhu yang lebih rendah dibandingkan jika tidak ada uap APLIKASI STERILISASI UAP UNTUK: Semua sediaan dan bahan yang tahan terhadap panasSemua sediaan dan bahan yang tahan terhadap panas pada suhu yang digunakan dan uap dapat berpenetrasi sediaan larutan dalam kemasan, ruahan larutan, alat- alat gelas, pakaian operasi dan peralatan operasi TIDAK UNTUK: Minyak, lemak, sediaan mengandung lemak, dan lain-lain yang tidak bisa dipenetrasi oleh uap Sediaan solid yang rusak oleh adanya lembap
  • 31. 4/18/2010 7 Faktor kritis yang mempengaruhi keberhasilan sterilisasi:ster l sas Suhu Waktu sterilisasi Kesempurnaan pergantian udara dengan uap (tidak boleh ada udara yang terjerap) Efektif terhadap semua jenis mikroorganismef f p j g termasuk spora Menguraikan asam nukleat, protein dan membran TEKANAN VS SUHU VS WAKTU Tekanan Suhu Waktu 10 115.5 30 15 121.5 20 20 126.5 15 Tekanan suhu waktu
  • 32. 4/18/2010 8 STERILISASI PANAS KERING Umumnya dilakukan di oven, baik dengan sistem pemanas gas atau listrik dengan suhu terkontrol Sterilisasi dengan cara panas kering kurang efisien dibandingkan dengan cara basah sehingga: Memerlukan waktu yang lebih lama (2-4 jam) Memerlukan panas yang lebih tinggi (160-170C) Suhu dan waktu bergantung pada: Ukuran produk/sediaan Jenis produk/sediaan Jenis kemasan produk/sediaan Karakteristik distribusi panas Volume sekecil mungkin Alat pensteril mensirkulasi panas secara bebas dan menyeluruh
  • 33. 4/18/2010 9 APLIKASI STERILISASI PANAS KERING Minyaky Gliserin Petrolatum Parafin Serbuk tahan panas (ZnO) Alat-alat gelas Perlengkapan operasi STERILISASI FILTRASI Penghilangan mikroorganisme dilakukan dengan cara adsorpsi pada medium filter atau mekanismep p m m f m m penapisan Digunakan untuk produk atau bahan yang sensitif terhadap panas, dan hanya untuk LARUTAN Efektivitas sterilisasi dipengaruhi oleh jumlah kandungan mikroba dalam larutan
  • 34. 4/18/2010 10 JENIS-JENIS FILTER 1. Filter berbentuk tabung reaksi filter candles, terbuat dari mineral yang dikompres (Berkefeld dan Mandler)dan Mandler) 2. Filter candles dari porselin (Pasteur-Chamberland, Doulton, Selas) 3. Filter keping terbuat dari asbes yang dikompres (Seitz dan Swinney) 4. Buchner 5. Millipore (terbaru) FAKTOR PENTING DALAM FILTRASI Uk i ( li ti )Ukuran pori (paling penting) Muatan listrik filter dan mikroba pH larutan Suhu TekananTekanan
  • 35. 4/18/2010 11 KEUNTUNGAN VS KERUGIAN METODE FILTRASI Cepat (terutama untuk volum kecil) M j t bilit d k/b h KEUNTUNGAN Menjaga stabilitas produk/bahan Relatif murah Sifat penghilangan mikroba dan partikulat lainnya sempurna KERUGIAN Sifat adsorpsi zat tertentu (zat aktif) yang tidak diinginkan terutama yang jumlahnya kecil Terbatas penggunaannya untuk larutan-larutan viskus STERILISASI GAS Digunakan terutama untuk bahan yang tidak tahan panas dan lembap Bi s n dik mbin si den n t kl f: ut cl veBiasanya dikombinasi dengan otoklaf: autoclave- ethylene oxide sterilizer dan perlu pertimbangan: waktu, suhu, konsentrasi gas dan kelembapan: Kelembapan sampai 60% dan suhu (50 dan 60C) dapat t sterilisasi Bahan yang tidak tahan lembap dan panasBahan yang tidak tahan lembap dan panas memerlukan t sterilisasi lebih lama Contoh gas pensteril: Etilen oksidandan propilen oksida
  • 36. 4/18/2010 12 ETILEN OKSIDA Sterilisasi dengan cara mengganggu metabolisme sel bakteri Digunakan untuk sterilisasi produk yang tidak dapat disterilkan dengan uapg p Berupa gas tidak berwarna Mudah terbakar dan meledak Pemakaiannya terbatas Keuntungan: Dapat digunakan untuk sterilisasi bahan yang sensitif terhadap panas dan lembap (perlengkapan operasi, senyawa enzim, antibiotik) karena kemampuan penetrasinya yang baik Kerugian:Kerugian: Memerlukan waktu lama (4-16 jam) Mahal Berbahaya untuk pasien dan pekerja Perlu pengecekan setelah sterilisasi untuk menjamin tidak terjadinya reaksi kimia dan penguaraian pada bahan Toksisitas metode sterilisasi dengan gas ETO
  • 37. 4/18/2010 13 STERILISASI DENGAN RADIASI Sterilisasi menggunakan sinar gamma dan radiasi katoda Mekanisme kerja sterilisasi dengan radiasi belum diketahui secara pasti, teori menyebutkan terjadinya perubahan kimia destruktif pada mikroba yang dapat merusak sel secara sempurna dan ireversibel RADIASI UV Terbatas pada permukaan bahan karena UV tidak dapat berpenetrasi ke dalam elas air lapisan dandapat berpenetrasi ke dalam gelas, air, lapisan dan zat lain Sudah digunakan untuk pengolahan air
  • 38. 4/18/2010 14 STERILISASI DENGAN PELARUT ORGANIK Fenol Alkohol Formaldehid
  • 40. 4/18/2010 16 NILAI F Untuk mengkuantifikasi efektivitas proses sterilisasi panas digunakan bilangan F (time of thermal death) yaitu waktu yang diperlukan untuk membunuhyaitu waktu yang diperlukan untuk membunuh organisme tertentu pada suatu kondisi Nilai F dihitung dari data biologi yang diturunkan dari kecepatan destruksi dari sejumlah mikroba, dengan persamaan: Fo = D121 (Log A – Log B) A : populasi mikroba awal B : jumlah mikroba yang hidup setelah waktu pemanasan tertentu PIROGEN DAN UJI PIROGEN PIROGEN : senyawa organik yang dapat menimbulkan demam berasal dari kontaminasi mikrobademam, berasal dari kontaminasi mikroba Materi penyebabnya adalah LPS dari dinding luar sel bakteri dan endotoksin Pirogen termasuk senyawa yang termostabil sehingga kemungkinan masih tertinggal dalam sediaan larutankemungkinan masih tertinggal dalam sediaan larutan setelah proses sterilisasi dengan otoklaf maupun filtrasi
  • 41. 4/18/2010 17 PEMBEBASAN PIROGEN DAN UJI PIROGEN Pirogen (dalam air pro injeksi) dihilangkan dengan adsorpsi menggunakan karbon aktif carip m gg f prosedurnya! Uji pirogen menurut USP dilakukan pada hewan kelinci cari prosedurnya! PENGEMBANGAN SEDIAAN STERIL LIQUID SEMI SOLID SOLID Suspensi Emulsi Larutan bebas partikulat- bebas partikulat - isotonis, terutama untuk volume besar dan intravena - isohidris, idem (kapasitas dapar rendah) - Bebas pirogen (terutama iv volume > 10 ml)
  • 42. 4/18/2010 18 OBAT SUNTIK S di b l t l i t i d l iSediaan berupa larutan, emulsi atau suspensi dalam air atau pembawa lain yang sesuai, steril dan digunakan secara parenteral Berdasarkan volumnya dibagi menjadi 2: 1. Volume kecil (berupa larutan atau suspensi, <10 ml) 2 Volume besar (berupa larutan >=100 ml diberikan2. Volume besar (berupa larutan >=100 ml, diberikan sebagai infus intravena) Contoh produk: “pharmaceutical dosage forms & dds” LARGE VOLUME PARENTERAL (LVP) Diberikan umumnya untuk penggantian cairan tubuh, elektrolit atau nutrisi; terapi perawatan, ; p p w paska operasi, pasien tidak sadar dan tidak bisa menerima cairan, elektrolit dan nutrisi melalui rute oral Volume >= 100 ml per hari secara infus iv, dengan atau tanpa kontrol kecepatan pemberian Karena volumenya yang besar sediaan tidakKarena volumenya yang besar, sediaan tidak boleh mengandung pengawet (bakteriostatik) atau zat tambahan lain Kemasan umumnya single dose next: lihat “Pharmaceutical dosage forms & DDS”
  • 43. 4/18/2010 19 KLASIFIKASI OBAT SUNTIK 1. Bentuk sediaan Larutan sejati pembawa air Larutan sejati pembawa minyak Larutan sejati pembawa pelarut campur Suspensi steril pembawa air Suspensi steril pembawa minyak Serbuk rekonstitusi Emulsi steril 2. Rute pemberian Iv, im, sk, ik, ip, dan lain-lain, , , , p,
  • 44. 4/18/2010 20 BAHAN PEMBAWA OBAT SUNTIK 1. AIR Ai i j k iAir pro injeksi Aquabidest dengan pH tertentu, tidak mengandung logam berat, tidak mengandung ion Ca, Cl, NO3, SO4, Nh4, NO2 dan CO3 Harus steril, penggunaan dalam jumlah besar harus bebas pirogen Nilai tahanan spesifik sebesar 500.000 ohm/cm, jik il i h k tid k b l h di kjika nilainya separuhnya maka tidak boleh digunakan Aqua demineralisata tidak boleh digunakan sebagai pembawa obat suntik Air pro injeksi bebas CO2 Dibuat dengan cara mendidihkan air pro injeksi selama 20-30 menit, lalu dialiri gas N2 sambil didinginkan Air pro injeksi bebas O2 Dibuat dengan cara mendidihkan air pro injeksi selama 20-30 menit, jika dibutuhkan dalam jumlah besar maka dialiri N2 sambil didinginkandidinginkan Digunakan untuk melarutkan zat aktif yang mudah teroksidasi (klorpromazin, prometazin, klorfeniramin, sulfamidin, dan lain-lain)
  • 45. 4/18/2010 21 2. Non air Digunakan jika: Zat aktif tidak larut dalam pembawa air k f d l bZat aktif terurai dalam pembawa air Diinginkan kerja depo dari sediaan Minyak tumbuhan Mudah tengik karena mengandung asam lemak bebas (+ antioksidan) Tidak boleh mengandung minyak mineral atau parafin cair karena tidak bisa dimetabolisme dalam tubuh, karsinogenik, dan memberikan reaksi terhadap jaringan Sering menimbulkan rasa nyeri sehingga perlu penambahan benzil alkohol 5% untuk anestesi lokal Jenis minyak tumbuhan yang digunakan: Ol. Arachidis Ol. SesamiOl. Sesami Ol.Gossypii Ol. Olivarum netral Ol Terebintinae Ol.Maidis Ol.Amygdalarumyg
  • 46. 4/18/2010 22 Minyak semi sintesis Ester asam lemak AlkoholAlkohol Memiliki aktivitas fisiologis, menimbulkan rasa nyeri dan kerusakan jaringan pada penggunaannya sehingga pemberiannya secara iv tidak disarankan FAKTOR YANG MEMPENGARUHI ABSORPSI OBAT SUNTIK Rute pemberian (iv > im > sk)Rute pemberian (iv > im > sk) Ukuran partikel zat aktif (makin halus makin cepat) Polimorfisma (amorf > kristal) Bentuk sediaan (larutan > emulsi > suspensi) Pembawa (air > minyak)( y ) pH (untuk rute im dan sk isohidrisitas sangat penting, iv tidak karena volume darah yang besar dengan kapasitas dapar mampu menetralkan)
  • 47. 4/18/2010 23 TONISITAS LARUTAN OBAT SUNTIK ISOTONIS Jika suatu larutan konsentrasinya sama dengan konsentrasiJika suatu larutan konsentrasinya sama dengan konsentrasi dalam sel darah merah sehingga tidak terjadi pertukaran cairan diantara keduanya ISOOSMOTIK Jika suatu larutan mempunyai tekanan osmotik yang sama dengan tekanan osmotik serum HIPOTONIS Jika tekanan osmosis sediaan lebih rendah dari tekanan osmosis serum darah, menyebabkan air akan melintasi membran sel darah merah yang semipermeabel memperbesar volume menyebabkan peningkatan tekanan dalam sel pecah hemolisis HIPERTONI Jika tekanan osmosis sediaan lebih besar dari tekanan serum darah, menyebabkan air keluar dari sel darah merah melintasi membran semipermeabel mengakibatkan penciutan sel-sel darah merah plasmolisism p m TONISITAS MODIFIER NaCl Glukosa Sukrosa KNO3 NaNO3